RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Drug delivery to the nasal cavity has been achieved using a variety of systems. Dry powder vaccines offer the advantages of chemical and physical stability in comparison to liquid formulations. An intranasal vaccine can elicit both a local and systemic immune response. Mucoadhesive compounds can extend the residence time for powder formulations on the nasal mucosa, potentially increasing the immune response. Manufacture and characterization of a formulation containing particles of a dry powder vaccine are discussed
